Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment

Giulio Antonelli, Elia Gigante, Massimo Iavarone, Paola Begini, Angelo Sangiovanni, Elsa Iannicelli, Piero Biondetti, Adriano M. Pellicelli, Lucia Miglioresi, Paolo Marchetti, Pietro Lampertico, Massimo Marignani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours. Objective: Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods: We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory, treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an L3 section CT image. Results: Sarcopenia was present in 49% of patients. Patients were divided into two groups according to sarcopenia: age was significantly higher in the sarcopenic group (SG) (66 years (31–87) versus 72 years (30–84), p = 0.04], with no difference in other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95% confidence interval (CI) 26–50) versus 61 (95% CI 47–77) weeks (p = 0,01)) and shorter time on treatment (12.3 (95% CI 8–19) versus 25.9 (95% CI 15–33) weeks (p = 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p = 0.03) and reduced time on treatment (p = 0.001). Conclusion: Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and reduced duration of oral chemotherapy.

Original languageEnglish
Pages (from-to)1039-1048
JournalUnited European Gastroenterology Journal
Volume6
Issue number7
DOIs
Publication statusPublished - 2018

Fingerprint

Sarcopenia
Hepatocellular Carcinoma
Survival
Confidence Intervals
Therapeutics
Tomography
sorafenib
Multicenter Studies
Skeletal Muscle
Fibrosis
Multivariate Analysis
Retrospective Studies
Drug Therapy

Keywords

  • CT scan
  • HCC
  • performance status
  • prognostic factor
  • skeletal muscle index

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. / Antonelli, Giulio; Gigante, Elia; Iavarone, Massimo; Begini, Paola; Sangiovanni, Angelo; Iannicelli, Elsa; Biondetti, Piero; Pellicelli, Adriano M.; Miglioresi, Lucia; Marchetti, Paolo; Lampertico, Pietro; Marignani, Massimo.

In: United European Gastroenterology Journal, Vol. 6, No. 7, 2018, p. 1039-1048.

Research output: Contribution to journalArticle

Antonelli, Giulio ; Gigante, Elia ; Iavarone, Massimo ; Begini, Paola ; Sangiovanni, Angelo ; Iannicelli, Elsa ; Biondetti, Piero ; Pellicelli, Adriano M. ; Miglioresi, Lucia ; Marchetti, Paolo ; Lampertico, Pietro ; Marignani, Massimo. / Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. In: United European Gastroenterology Journal. 2018 ; Vol. 6, No. 7. pp. 1039-1048.
@article{8520cd2e9001454ea37242ea48690471,
title = "Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment",
abstract = "Background: Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours. Objective: Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods: We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory, treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an L3 section CT image. Results: Sarcopenia was present in 49{\%} of patients. Patients were divided into two groups according to sarcopenia: age was significantly higher in the sarcopenic group (SG) (66 years (31–87) versus 72 years (30–84), p = 0.04], with no difference in other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95{\%} confidence interval (CI) 26–50) versus 61 (95{\%} CI 47–77) weeks (p = 0,01)) and shorter time on treatment (12.3 (95{\%} CI 8–19) versus 25.9 (95{\%} CI 15–33) weeks (p = 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p = 0.03) and reduced time on treatment (p = 0.001). Conclusion: Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and reduced duration of oral chemotherapy.",
keywords = "CT scan, HCC, performance status, prognostic factor, skeletal muscle index",
author = "Giulio Antonelli and Elia Gigante and Massimo Iavarone and Paola Begini and Angelo Sangiovanni and Elsa Iannicelli and Piero Biondetti and Pellicelli, {Adriano M.} and Lucia Miglioresi and Paolo Marchetti and Pietro Lampertico and Massimo Marignani",
year = "2018",
doi = "10.1177/2050640618781188",
language = "English",
volume = "6",
pages = "1039--1048",
journal = "United European Gastroenterology Journal",
issn = "2050-6406",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment

AU - Antonelli, Giulio

AU - Gigante, Elia

AU - Iavarone, Massimo

AU - Begini, Paola

AU - Sangiovanni, Angelo

AU - Iannicelli, Elsa

AU - Biondetti, Piero

AU - Pellicelli, Adriano M.

AU - Miglioresi, Lucia

AU - Marchetti, Paolo

AU - Lampertico, Pietro

AU - Marignani, Massimo

PY - 2018

Y1 - 2018

N2 - Background: Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours. Objective: Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods: We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory, treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an L3 section CT image. Results: Sarcopenia was present in 49% of patients. Patients were divided into two groups according to sarcopenia: age was significantly higher in the sarcopenic group (SG) (66 years (31–87) versus 72 years (30–84), p = 0.04], with no difference in other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95% confidence interval (CI) 26–50) versus 61 (95% CI 47–77) weeks (p = 0,01)) and shorter time on treatment (12.3 (95% CI 8–19) versus 25.9 (95% CI 15–33) weeks (p = 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p = 0.03) and reduced time on treatment (p = 0.001). Conclusion: Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and reduced duration of oral chemotherapy.

AB - Background: Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours. Objective: Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods: We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory, treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an L3 section CT image. Results: Sarcopenia was present in 49% of patients. Patients were divided into two groups according to sarcopenia: age was significantly higher in the sarcopenic group (SG) (66 years (31–87) versus 72 years (30–84), p = 0.04], with no difference in other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95% confidence interval (CI) 26–50) versus 61 (95% CI 47–77) weeks (p = 0,01)) and shorter time on treatment (12.3 (95% CI 8–19) versus 25.9 (95% CI 15–33) weeks (p = 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p = 0.03) and reduced time on treatment (p = 0.001). Conclusion: Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and reduced duration of oral chemotherapy.

KW - CT scan

KW - HCC

KW - performance status

KW - prognostic factor

KW - skeletal muscle index

UR - http://www.scopus.com/inward/record.url?scp=85047943609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047943609&partnerID=8YFLogxK

U2 - 10.1177/2050640618781188

DO - 10.1177/2050640618781188

M3 - Article

AN - SCOPUS:85047943609

VL - 6

SP - 1039

EP - 1048

JO - United European Gastroenterology Journal

JF - United European Gastroenterology Journal

SN - 2050-6406

IS - 7

ER -